4TEEN4 Pharmaceuticals

Overview

4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) today announced the extension of its Series C financing to €55 million ($64 million), with participation from existing and new investors. The capital will fund the further development of procizumab in patients with shock caused primarily by cardiogenic events. The proceeds will also be used to increase the footprint of the PROCARD 2a study across Europe and to support the planned expansion in the U.S., thereby broadening patient access to procizumab and strengthening operational readiness ahead of the pivotal trial. Procizumab is 4TEEN4’s proprietary monoclonal antibody, designed to neutralize circulating dipeptidyl peptidase 3 (cDPP3), a cardiac depression factor and key pathological driver in shock. Shock is a life-threatening condition characterized by acute circulatory failure resulting from end-stage disease or sudden critical events. The condition often leads to multi-organ failure and is associated with mortality rates exceeding 50%. The ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2a trial is evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of procizumab, in patients with cardiogenic shock and elevated cDPP3 levels. The company announced the dosing of the first patient in July 2025 and expects the first interim PK/PD and safety results in early 2026. “This financing reflects a strong vote of confidence in 4TEEN4’s mission and the transformative potential of our science to improve survival in critically ill patients,” said Dr. Andreas Bergmann, CEO of 4TEEN4 Pharmaceuticals. “This investment enables us to advance our PROCARD 2a study, creating a comprehensive framework for our planned pivotal study for procizumab. Together with our investors, we are progressing toward delivering a breakthrough therapy that moves beyond supportive care for patients with life-threatening shock.”